2.5.2012

Amendment 1 Monica Luisa Macovei on behalf of the PPE Group

Report

Monica Luisa Macovei Discharge 2010: European Medicines Agency COM(2011)0473 – C7-0281/2011 – 2011/2220(DEC)

Motion for a resolution Paragraph 28

Motion for a resolution

28. Is seriously concerned by the failure of the Agency and its Management Board to effectively address the matter of conflict of interests;

Amendment

28. Is seriously concerned by the failure of the Agency and its Management Board to effectively address the matter of conflict of interests; takes note that in April 2012 the Agency adopted a revised policy on the handling of conflicts of interests of Scientific Committee members and experts, as well as a breach of trust procedure for Committee members and experts; insists that implementation and concrete results are the only elements to prove the efficiency of the new policy and procedure; believes that the Agency should verify, during 2012, all declarations of interest of experts and Scientific Committee members; therefore, calls on the Agency to provide data figures and names included - following the enforcement of this procedure; calls also on the Agency to have verified at least 75 % of the experts' declarations of interest and at least 75 % of the Scientific Committee members' declarations of interest and to provide the discharge authority with the verification results and with an Action Plan with a calendar concerning the rest of the verification process for declarations of interest by the end of August 2012;

Or. en

AM\P7_AMA(2012)0107(001-004)_EN.doc

PE486.792v01-00

A7-0107/2012

2.5.2012

Amendment 2 Edit Herczog

Report Monica Luisa Macovei Discharge 2010: European Medicines Agency COM(2011)0473 – C7-0281/2011 – 2011/2220(DEC)

Motion for a resolution Paragraph 18

Motion for a resolution

18. Notes that by refusing a new payment system, the Management Board accepts and takes direct responsibility for very important risks, such as non-compliance with legislative requirements, the potential financial impact of the current remuneration system, and reputation; is therefore not ready to accept this questionable attitude from the Management Board and calls on the Agency to adopt an Action Plan on this matter and to inform the discharge authority by 30 June 2012; Amendment

18. *Calls* on the Agency to adopt an Action Plan *with a view to adopting* and *implementing a new payment system and* to inform the discharge authority by 30 June 2012;

Or. en

PE486.792v01-00

AM\P7_AMA(2012)0107(001-004)_EN.doc

A7-0107/2012

deleted

28. Is seriously concerned by the failure of the Agency and its Management Board to effectively address the matter of conflict of interests;

Motion for a resolution

Motion for a resolution Paragraph 28

Amendment 3 Edit Herczog on behalf of the S&D Group

2.5.2012

Report Monica Luisa Macovei Discharge 2010: European Medicines Agency COM(2011)0473 – C7-0281/2011 – 2011/2220(DEC)

on behalf of the S&D Group

A7-0107/3

A7-0107/2012

Amendment

Or. en

2.5.2012

Amendment 4 **Edit Herczog** on behalf of the S&D Group

Report

Monica Luisa Macovei Discharge 2010: European Medicines Agency COM(2011)0473 - C7-0281/2011 - 2011/2220(DEC)

Motion for a resolution Paragraph 36

Motion for a resolution

36. Notes that the Agency has been audited by the Court of Auditors in the framework of the Special Report on conflicts of interest management in the Union agencies; acknowledges from the Court of Auditors that the above-mentioned Special Report will be published by the end of June 2012; is of the opinion that, given the extent of criticisms questioning conflict of interest issues in the Agency, the decision on discharge should be postponed until the publication of the Special Report to take into account the findings of the *Court of Auditors in this respect;*

Amendment

36. Notes that the Agency has been audited by the Court of Auditors in the framework of the Special Report on conflicts of interest management in the Union agencies; acknowledges from the Court of Auditors that the above-mentioned Special Report will be published by the end of June 2012;

Or. en

PE486.792v01-00

AM\P7 AMA(2012)0107(001-004) EN.doc

A7-0107/2012